Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBA6 | A0AVT1 | 3/20 | 0.35 |
| ▸ | RET | P07949 | 4/20 | 0.34 |
| ▸ | KIF5B | P33176 | 4/20 | 0.34 |
| ▸ | KDR | P35968 | 3/20 | 0.34 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.33 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.33 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | CCDC6 | Q16204 | 1/20 | 0.33 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | NNMT | P40261 | 7/20 | 0.32 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1933318 | 0.79 | RET (0.52) | RETKIF5BKDRKCNH2CCDC6 | |
| SCHEMBL1443270 | 0.78 | ADK (0.43) | RETKIF5BKDRTLR9TLR8 | |
| SCHEMBL27864278 | 0.78 | NNMT (0.33) | UBA6RETKIF5BKDRPIP4K2A | |
| SCHEMBL27864474 | 0.77 | RET (0.39) | RETKIF5BKDRPIP4K2APRMT5 | |
| SCHEMBL16769947 | 0.75 | PRMT5 (0.44) | UBA6PIP4K2APRMT5WDR77SLC22A12 | |
| SCHEMBL25611996 | 0.73 | PIP4K2A (0.44) | UBA6KDRPIP4K2APRMT5WDR77 | |
| SCHEMBL23892218 | 0.73 | PRMT5 (0.47) | UBA6PIP4K2APRMT5WDR77SLC22A12 | |
| SCHEMBL16769943 | 0.73 | SLC22A12 (0.40) | PIP4K2APRMT5WDR77SLC22A12NNMT | |
| SCHEMBL16967987 | 0.72 | PIP4K2A (0.49) | PIP4K2APRMT5WDR77SLC22A12 | |
| SCHEMBL16943626 | 0.71 | UBA6 (0.42) | UBA6PIP4K2APRMT5WDR77NNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2475668-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | Novartis AG (CH) | 2012-07-18 | — | — | EP | disclosed |
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2012-06-28 | — | — | US | disclosed |
| WO-2011029915-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | NOVARTIS AG (CH) | 2011-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165310-A1 | ETHER DERIVATIVES OF BICYCLIC HETEROARYLS | ETV6, CYP11B2, CYP11B1 | UBA6 3416/4885RET 853/4885KIF5B 2516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.